Skip to main content

Genmab A/S (GMAB)

NASDAQ: GMAB · IEX Real-Time Price · USD
46.73 0.34 (0.73%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap30.55B
Revenue (ttm)1.17B
Net Income (ttm)402.08M
Shares Out653.86M
EPS (ttm)0.59
PE Ratio78.60
Forward PE55.25
Dividendn/a
Ex-Dividend Daten/a
Volume203,258
Open46.50
Previous Close46.39
Day's Range46.45 - 46.88
52-Week Range30.10 - 49.07
Beta0.62
AnalystsBuy
Price Target42.14 (-9.8%)
Est. Earnings DateNov 10, 2021

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for tr...

IndustryBiotechnology
Founded1999
CEOJan van de Winkel
Employees1,029
Stock ExchangeNASDAQ
Ticker SymbolGMAB
Full Company Profile

Financial Performance

In 2020, Genmab A/S's revenue was 10.11 billion, an increase of 88.43% compared to the previous year's 5.37 billion. Earnings were 4.76 billion, an increase of 119.67%.

Financial numbers in millions DKKFinancial Statements

Analyst Forecast

According to 7 analysts, the average rating for Genmab A/S stock is "Buy." The 12-month stock price forecast is 42.14, which is a decrease of -9.82% from the latest price.

Price Target
$42.14
(-9.82% downside)
Analyst Consensus: Buy

News

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement

2 weeks ago - GlobeNewsWire

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs...

Other symbols:INCYSGENTAK
3 weeks ago - Benzinga

Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immuno...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational therapies and technologies in the company's solid tumor product...

3 weeks ago - Business Wire

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

1 month ago - GlobeNewsWire

FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer

The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S' (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent or metast...

Other symbols:SGEN
1 month ago - Benzinga

Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurr...

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated a...

Other symbols:SGEN
1 month ago - Business Wire

Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurr...

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated a...

Other symbols:SGEN
1 month ago - Business Wire

Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer

Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV) in re...

Other symbols:SGEN
1 month ago - Benzinga

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hod...

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/...

Other symbols:ABBV
1 month ago - Business Wire

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hod...

NORTH CHICAGO, Ill., and COPENHAGEN, Denmark, Sept, 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part...

Other symbols:ABBV
1 month ago - PRNewsWire

Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Media Release Copenhagen, Denmark, 2 7 August, 202 1

1 month ago - GlobeNewsWire

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

2 months ago - GlobeNewsWire

Genmab Announces Financial Results for the First Half of 2021

August 1 1 , 20 2 1 ; Copenhagen, Denmark; Interim Report for the First Half of 20 2 1

2 months ago - GlobeNewsWire

Is a Surprise Coming for Genmab (GMAB) This Earnings Season?

Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Major Shareholder Announcement

Company Announcement

3 months ago - GlobeNewsWire

Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs

Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?

Other symbols:BEAMBOLTMGNXZLAB
3 months ago - PennyStocks

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

3 months ago - GlobeNewsWire

ALXN or GMAB: Which Is the Better Value Stock Right Now?

ALXN vs. GMAB: Which Stock Is the Better Value Option?

3 months ago - Zacks Investment Research

Completion of share buy-back program

Company Announcement

3 months ago - GlobeNewsWire

Transactions in connection with share buy-back program

Company Announcement

3 months ago - GlobeNewsWire

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement

4 months ago - GlobeNewsWire